Heuking advises Viromed Medical AG on IPO
November, 2022 - Germany
A team led by Dr. Thorsten Kuthe, Partner at Heuking Kühn Lüer Wojtek’s Cologne office, advised Viromed Medical AG in connection with its listing on Düsseldorf Stock Exchange.
By way of a capital increase through contributions in kind, Viromed Medical AG, formerly Fonterelli SPAC2 AG, acquired 100 % of Viromed Medical GmbH, which operates in the distribution of products in diagnostics, therapeutics, and cold plasma technology. The company has a broad customer base in the German-speaking regions, including various DAX companies such as Volkswagen and Lufthansa, as well as German states and the Federal Ministry of Health, 1,100 hospitals, 7,000 pharmacies, and 11,000 medical practices.
The acquisition of Viromed Medical GmbH increased the number of shares in Viromed Medical AG to 20,250,000 of which 68 % are held by the entrepreneurial Perbandt family based in Rellingen, while the remaining shares are in free float.
The Heuking team advised the stock corporation on the IPO and on the acquisition of the shares of Viromed Medical GmbH.
Counsel to Viromed Medical AG
Heuking Kühn Lüer Wojtek:
Dr. Thorsten Kuthe (Lead),
Stefan Westerheide, LL.M. oec, both Capital Markets, both Cologne
